Traditional markers of LN, such as increased native double-stranded DNA antibody (anti-dsDNA) and decreased C3 and C4 complement fractions, are currently used in the clinical assessment of LN [5]; however, these markers do not appear to have sufficient sensitivity for detecting LN in a subgroup of SLE patients, thus, new non-traditional markers should be tested [6]. This evidence concerns the gene C3 and lobular neoplasia.